Product Code: 978-1-68038-509-0
Inhalation Anesthesia Market Growth & Trends
The global inhalation anesthesia market size is expected to reach USD 2.92 billion by 2030, registering a CAGR of 9.04%, according to a new report by Grand View Research, Inc. Inhalation anesthetics offer shorter induction period and recovery time along with better efficacy and lesser adverse effects as compared to other alternatives, thus providing better anesthetic effect during surgical procedures. They also provide excellent control over the duration of anesthesia in the patient. Thus, inhalation anesthesia is being preferred over intravenous anesthesia due to these advantages.
Drugs administered through inhalation anesthesia have a quick onset of action even at low dose as compared to intravenous anesthesia. Using inhalation route for administration helps avoid excessive dosage and keeps the patient's autonomic functions intact. As these drugs are eliminated via lungs, they have lower chances of accumulation in the body. Hence, they result in lower risk of hepatotoxicity. In addition, drugs administered through inhalation route have limited tolerance and addiction level as compared to other alternatives routes.
With the launch of innovative respiratory products such as AnaConDa (Anaesthetic Conserving Device), administration of inhalation general anesthetic agents such as sevoflurane, isoflurane, & other agents have become easier. Inhalation anesthesia is considered to be the best alternative for patients who are on ventilation for more than 24 hours as it becomes easy to monitor the patient's health.
Major concern associated with anesthetic gas is that only 5% account for patient use and the rest 95% is released in the atmosphere, which leads to greenhouse effect of these gases. The comparative analysis of sevoflurane, isoflurane, and desflurane based on atmospheric time span and global atmospheric concentrations indicates that desflurane poses a high potential threat for environment.
Inhalation Anesthesia Market Report Highlights
- Sevoflurane held the largest market share in 2022, due to the fact that its pharmacokinetics and pharmacodynamics leads to many advantages over other alternate inhaled anesthetic agents available.
- Desflurane, alone or in combination with nitrous oxide or other inhalation anesthetic agents is used in various surgical procedures owing to its rapid onset of action and elimination rate; therefore, driving the segment demand.
- There have been many complications reported with halothane, for instance, halothane-induced hepatitis; therefore, this anesthetic agent has been discontinued in the majority of the western countries.
- North America dominated the market in 2022 due to the high demand for sevoflurane and desflurane in the region. Key companies are also undertaking various strategic initiatives that has led to their high revenue growth in the U.S.
- China is the largest economy in Asia Pacific. It is a country with the maximum population in the world, hence having a large patient pool for surgeries. A large number of surgeries being performed along with the presence of a large patient pool is anticipated to boost the market over the forecast period.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1 Market Segmentation and Scope
- 1.1.1 Segment Definitions
- 1.1.1.1 Test Segment
- 1.1.1.2 Service Provider Segment
- 1.1.1.3 Application Segment
- 1.2 Regional Scope
- 1.3 Estimates And Forecast Timeline
- 1.4 Objectives
- 1.4.1 Objective - 1
- 1.4.2 Objective - 2
- 1.4.3 Objective - 3
- 1.5 Research Methodology
- 1.6 Information Procurement
- 1.6.1 Purchased Database
- 1.6.2 Gvr's Internal Database
- 1.6.3 Secondary Sources
- 1.6.4 Primary Research
- 1.7 Information Or Data Analysis
- 1.7.1 Data Analysis Models
- 1.8 Market Formulation & Validation
- 1.9 Model Details
- 1.9.1 Commodity Flow Analysis
- 1.10 List of Secondary Sources
- 1.11 List of Abbreviations
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Segmentation and Scope
- 3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
- 3.3. Market Dynamics
- 3.3.1. Higher patient outcome as compared to intravenous anesthesia.
- 3.3.2. Increasing need to reduce hospital care cost
- 3.3.3. Rising number of surgical procedures
- 3.4. Market restraint analysis
- 3.4.1. Increasing concern about greenhouse gas emissions
- 3.5. Porter's Five Forces Analysis
- 3.6. PESTLE Analysis
- 3.7. Pipeline Analysis
Chapter 4. Drug Type Business Analysis
- 4.1. Global Inhalation Anesthesia Market: Drug Movement Analysis
- 4.2. Sevoflurane
- 4.2.1. Sevoflurane market estimates and forecasts, 2018 - 2030 (USD million)
- 4.3. Desflurane
- 4.3.1. Desflurane market estimates and forecasts, 2018 - 2030 (USD million)
- 4.4. Isoflurane
- 4.4.1. Isoflurane market estimates and forecasts, 2018 - 2030 (USD million)
- 4.5. Others
- 4.5.1. Others market estimates and forecasts, 2018 - 2030 (USD million)
Chapter 5. Application Business Analysis
- 5.1. Global Inhalation Anesthesia Market: Application Movement Analysis
- 5.2. Induction
- 5.2.1. Induction market estimates and forecasts, 2018 - 2030 (USD million)
- 5.3. Maintenance
- 5.3.1. Maintenance estimates and forecasts, 2018 - 2030 (USD million)
Chapter 6. End-use Business Analysis
- 6.1. Global Inhalation Anesthesia Market: End-use Movement Analysis
- 6.2. Hospitals
- 6.2.1. S Hospitals market estimates and forecasts, 2018 - 2030 (USD million)
- 6.3. Ambulatory Surgical Centers
- 6.3.1. Ambulatory surgical centers market estimates and forecasts, 2018 - 2030 (USD million)
- 6.4. Others
- 6.4.1. Others market estimates and forecasts, 2018 - 2030 (USD million)
Chapter 7. Regional Business Analysis
- 7.1. Inhalation Anesthesia Market Share By Region, 2022 & 2030
- 7.2. North America
- 7.2.1. North America Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
- 7.2.2.1. Key Country Dynamics
- 7.2.2.2. Target Disease Prevalence
- 7.2.2.3. Competitive Scenario
- 7.2.2.4. Regulatory Framework
- 7.2.2.5. Reimbursement Scenario
- 7.2.2.6. U.S. Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.2.3. Canada
- 7.2.3.1. Key Country Dynamics
- 7.2.3.2. Target Disease Prevalence
- 7.2.3.3. Competitive Scenario
- 7.2.3.4. Regulatory Framework
- 7.2.3.5. Reimbursement Scenario
- 7.2.3.6. Canada Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.3. Europe
- 7.3.1. Europe Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.3.2. Germany
- 7.3.2.1. Key Country Dynamics
- 7.3.2.2. Target Disease Prevalence
- 7.3.2.3. Competitive Scenario
- 7.3.2.4. Regulatory Framework
- 7.3.2.5. Reimbursement Scenario
- 7.3.2.6. Germany Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.3.3. UK
- 7.3.3.1. Key Country Dynamics
- 7.3.3.2. Target Disease Prevalence
- 7.3.3.3. Competitive Scenario
- 7.3.3.4. Regulatory Framework
- 7.3.3.5. Reimbursement Scenario
- 7.3.3.6. UK Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.3.4. France
- 7.3.4.1. Key Country Dynamics
- 7.3.4.2. Target Disease Prevalence
- 7.3.4.3. Competitive Scenario
- 7.3.4.4. Regulatory Framework
- 7.3.4.5. Reimbursement Scenario
- 7.3.4.6. France Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.3.5. Italy
- 7.3.5.1. Key Country Dynamics
- 7.3.5.2. Target Disease Prevalence
- 7.3.5.3. Competitive Scenario
- 7.3.5.4. Regulatory Framework
- 7.3.5.5. Reimbursement Scenario
- 7.3.5.6. Italy Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.3.6. Spain
- 7.3.6.1. Key Country Dynamics
- 7.3.6.2. Target Disease Prevalence
- 7.3.6.3. Competitive Scenario
- 7.3.6.4. Regulatory Framework
- 7.3.6.5. Reimbursement Scenario
- 7.3.6.6. Spain Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.3.7. Denmark
- 7.3.7.1. Key Country Dynamics
- 7.3.7.2. Target Disease Prevalence
- 7.3.7.3. Competitive Scenario
- 7.3.7.4. Regulatory Framework
- 7.3.7.5. Reimbursement Scenario
- 7.3.7.6. Denmark Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.3.8. Sweden
- 7.3.8.1. Key Country Dynamics
- 7.3.8.2. Target Disease Prevalence
- 7.3.8.3. Competitive Scenario
- 7.3.8.4. Regulatory Framework
- 7.3.8.5. Reimbursement Scenario
- 7.3.8.6. Sweden Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.3.9. Norway
- 7.3.9.1. Key Country Dynamics
- 7.3.9.2. Target Disease Prevalence
- 7.3.9.3. Competitive Scenario
- 7.3.9.4. Regulatory Framework
- 7.3.9.5. Reimbursement Scenario
- 7.3.9.6. Norway Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.4.2. Japan
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Target Disease Prevalence
- 7.4.2.3. Competitive Scenario
- 7.4.2.4. Regulatory Framework
- 7.4.2.5. Reimbursement Scenario
- 7.4.2.6. Japan Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.4.3. China
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Target Disease Prevalence
- 7.4.3.3. Competitive Scenario
- 7.4.3.4. Regulatory Framework
- 7.4.3.5. Reimbursement Scenario
- 7.4.3.6. China Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.4.4. India
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Target Disease Prevalence
- 7.4.4.3. Competitive Scenario
- 7.4.4.4. Regulatory Framework
- 7.4.4.5. Reimbursement Scenario
- 7.4.4.6. India Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.4.5. South Korea
- 7.4.5.1. Key Country Dynamics
- 7.4.5.2. Target Disease Prevalence
- 7.4.5.3. Competitive Scenario
- 7.4.5.4. Regulatory Framework
- 7.4.5.5. Reimbursement Scenario
- 7.4.5.6. South Korea Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.4.6. Australia
- 7.4.6.1. Key Country Dynamics
- 7.4.6.2. Target Disease Prevalence
- 7.4.6.3. Competitive Scenario
- 7.4.6.4. Regulatory Framework
- 7.4.6.5. Reimbursement Scenario
- 7.4.6.6. Australia Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
- 7.4.7.1. Key Country Dynamics
- 7.4.7.2. Target Disease Prevalence
- 7.4.7.3. Competitive Scenario
- 7.4.7.4. Regulatory Framework
- 7.4.7.5. Reimbursement Scenario
- 7.4.7.6. Thailand Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.5. Latin America
- 7.5.1. Latin America Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Target Disease Prevalence
- 7.5.2.3. Competitive Scenario
- 7.5.2.4. Regulatory Framework
- 7.5.2.5. Reimbursement Scenario
- 7.5.2.6. Brazil Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.5.3. Mexico
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Target Disease Prevalence
- 7.5.3.3. Competitive Scenario
- 7.5.3.4. Regulatory Framework
- 7.5.3.5. Reimbursement Scenario
- 7.5.3.6. Mexico Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.5.4. Argentina
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Target Disease Prevalence
- 7.5.4.3. Competitive Scenario
- 7.5.4.4. Regulatory Framework
- 7.5.4.5. Reimbursement Scenario
- 7.5.4.6. Argentina Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.6. MEA
- 7.6.1. MEA Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.6.2. South Africa
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Target Disease Prevalence
- 7.6.2.3. Competitive Scenario
- 7.6.2.4. Regulatory Framework
- 7.6.2.5. Reimbursement Scenario
- 7.6.2.6. South Africa Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.6.3. Saudi Arabia
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Target Disease Prevalence
- 7.6.3.3. Competitive Scenario
- 7.6.3.4. Regulatory Framework
- 7.6.3.5. Reimbursement Scenario
- 7.6.3.6. Saudi Arabia Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.6.4. UAE
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Target Disease Prevalence
- 7.6.4.3. Competitive Scenario
- 7.6.4.4. Regulatory Framework
- 7.6.4.5. Reimbursement Scenario
- 7.6.4.6. UAE Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
- 7.6.5. Kuwait
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Target Disease Prevalence
- 7.6.5.3. Competitive Scenario
- 7.6.5.4. Regulatory Framework
- 7.6.5.5. Reimbursement Scenario
- 7.6.5.6. Kuwait Inhalation Anesthesia Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.2. Strategy Mapping
- 8.2.1. New Product Launch
- 8.2.2. Partnerships
- 8.2.3. Acquisition
- 8.2.4. Collaboration
- 8.2.5. Funding
- 8.3. Key Company Market Share Analysis, 2022
- 8.4. Company Heat Map Analysis
- 8.5. Company Profiles
- 8.5.1. HALOCARBON PRODUCTS CORPORATION
- 8.5.1.1. Company Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. BAXTER
- 8.5.2.1. Company Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. ABBVIE INC
- 8.5.3.1. Company Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. LUNAN PHARMACEUTICAL GROUP
- 8.5.4.1. Company Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. PIRAMAL ENTERPRISES LTD
- 8.5.5.1. Company Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. SANDOZ INTERNATIONAL GMBH
- 8.5.6.1. Company Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. FRESENIUS KABI AG
- 8.5.7.1. Company Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives